British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005

Christopher Griffiths, Catherine H. Smith, A. V. Anstey, J. N W N Barker, A. D. Burden, R. J G Chalmers, D. Chandler, A. Y. Finlay, C. E M Grifitths, K. Jackson, N. J. McHugh, K. E. McKenna, N. J. Reynolds, Anthony D. Ormerod

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Psoriasis is a common, persistent, relapsing inflammatory skin disease that can be associated with significant morbidity. Quality of life studies in psoriasis reveal a negative impact on patients comparable with that seen in cancer, arthritis and heart disease. Patients with severe disease constitute approximately 20-30% of all patients with psoriasis, often require systemic treatment, and represent a major economic burden to the Health Service. All standard systemic therapies for severe disease are associated with the potential for major long-term toxicity, many are expensive, and a proportion of patients has treatment-resistant disease. Biological therapies or 'biologics' describe agents designed to block specific molecular steps important in the pathogenesis of psoriasis and have emerged over the last 3-5 years as potentially valuable alternative therapeutic options. Currently, biological therapies for psoriasis comprise two main groups: (i) agents targeting the cytokine tumour necrosis factor (TNF)-α (e.g. etanercept, infliximab, adalimumab) and (ii) agents targeting T cells or antigen-presenting cells (e.g. efalizumab, alefacept). Two of these, etanercept (Enbrel®) and efalizumab (Raptiva®) were licensed in 2004 in the U.K. for patients with moderate to severe psoriasis. © 2005 British Association of Dermatologists.
    Original languageEnglish
    Pages (from-to)486-497
    Number of pages11
    JournalBritish Journal of Dermatology
    Volume153
    Issue number3
    DOIs
    Publication statusPublished - Sep 2005

    Keywords

    • Biologics
    • Efalizumab
    • Etanercept
    • Guideline
    • Infliximab
    • Psoriasis

    Fingerprint

    Dive into the research topics of 'British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005'. Together they form a unique fingerprint.

    Cite this